英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • SGO 2023 - ImmunoGen
    IMMUNOGEN IS NOW PART OF ABBVIE Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline
  • ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2010 Financial . . .
    WALTHAM, Mass , Jan 28, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended December 31, 2009 - the second quarter of the Company's
  • ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2009 Financial . . .
    ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three-month period ended December 31, 2008 – the second quarter of the Company’s 2009 fiscal year
  • SEC Filing | ImmunoGen, Inc.
    Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No 333-216438 PROSPECTUS Up to $50,000,000
  • SEC Filing | ImmunoGen, Inc.
    Immunogen Inc (Name of Issuer) Common (Title of Class of Securities) 45253H101 (CUSIP Number) March 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) o Rule 13d-1(c) o
  • SEC Filing | ImmunoGen, Inc.
    On January 31, 2007, ImmunoGen, Inc (Nasdaq: IMGN) announced the addition of Mr Howard Pien to the Company’s Board of Directors Mr Pien will also serve as a member of the Compensation Committee of the Board of Directors
  • SEC Filing | ImmunoGen, Inc.
    1 as filed with the securities and exchange commission on november 8, 1996 registration no 333- securities and exchange commission form s-3 registration statement under the securities act of 1933 ----- immunogen, inc
  • ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial . . .
    WALTHAM, Mass --(BUSINESS WIRE)--Aug 6, 2009-- ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the fiscal year and three-month period ended June 30, 2009
  • SEC Filing | ImmunoGen, Inc.
    - ----- ----- CUSIP No 45253H101 Page 1 of 8 Pages --- - ----- ----- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No 3) Immunogen, Inc - ----- (Name of Issuer) Common Stock, $ 01 par value per share - ----- (Title of Class of Securities) 45253H101
  • ImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419
    The compound was created by ImmunoGen and licensed to Sanofi as part of a broader collaboration The data reported today are from the Phase I evaluation that established the dosing schedule being used with SAR3419 in its Phase II evaluation





中文字典-英文字典  2005-2009